Athena Global Technologies Limited Overview
Athena Global Technologies is a Hyderabad-based micro-cap that began in 1991 as a software services and IT-education firm (VJIL Consulting) and now operates three disclosed reporting segments: offshore software services (application development, QA/testing, digital transformation, delivered mainly to US clients through its Schaumburg branch and a US subsidiary); real estate, which now drives the balance sheet; and online education through wholly owned subsidiary Tutoroot. The real estate asset is a 5-acre IT/SEZ development at Manikonda (Financial District) built under a joint development agreement with Phoenix Tech Zone. Healthcare-platform activity (MedleyMed) was restructured in March 2026. Economically, the company is now best understood as a promoter-controlled holding of a commercial real estate asset with a sub-scale software business attached. FY2024 included a ₹235.94 Cr non-cash fair-value gain on that property. Operating losses have persisted since FY2022, and debt has grown. The investment case depends on whether the property can be monetised through leasing or sale, starting with the 1,19,526 sq ft lease disclosed in September 2026.
Company's own description (FY2023-24 Annual Report, MD&A — paraphrased)
The company describes itself as a global provider of software application development, digital transformation, and QA & testing services to enterprises. The MD&A lists capabilities in:
-
AI services, such as real-time customer interaction and predictive/diagnostic applications
-
Blockchain solutions (described elsewhere by the company as built on Ethereum and Hyperledger)
-
Data science
-
IoT-based engagement solutions
-
Robotic process automation (RPA), chatbots and voicebots
-
Application development and product engineering
-
Production-environment support and QA
The MD&A also states a focus on enterprise information management, enterprise integration and data warehousing services. Client sectors named are financial services, healthcare, oil, pharmaceuticals, retail, business services, education, IT and government.
The FY2023-24 AR states that the company reports five segments on a consolidated basis:
-
Software services
-
Real estate
-
Online pharmacy platform services
-
Online trade of pharmaceutical products
-
Online education services
The S&P/Simply Wall St description adds several service lines:
-
Digitalisation of records and OCR technology
-
Governance, risk and compliance (GRC) consulting
-
Voice and non-voice technical support
-
Business process optimisation
-
Advisory, structuring and sustainability consulting
Screener's summary (citing the FY2022-23 AR) describes the business as software development and consulting, real estate activities, and IT-enabled business support services.
Business model and revenue model
| Dimension | Characterisation | Evidence |
|---|---|---|
| Software services | Mostly time-and-material and project-based offshore/onsite services; mainly export | FX earnings were ₹817.70 lakh in FY2024 against standalone revenue of ₹970.95 lakh (about 84% export) — FY2023-24 AR |
| Real estate | Investment property held at fair value under Ind AS 40; income from leasing / sale of built-up space | FY2024 investment property recognised at fair value of ₹23,900 lakh — FY2023-24 AR; lease of 1,19,526 sq ft at ₹11.19 Cr/yr from 27 Nov 2026 — BSE Reg. 30 filing, 18 Sep 2026 |
| Online education (Tutoroot) | B2C live online tutoring (subscription / course fees) for K-12 and competitive exams | Tutoroot launch coverage |
| Healthcare platforms (MedleyMed) | B2B pharmacy aggregation and ERP SaaS, e-pharmacy trading, and telemedicine SaaS | Business India feature; FY2023-24 AR |
| Mix | Product/licensing: negligible or not disclosed. Services: dominant in operating revenue. Subscription: small (education, SaaS). Real estate rental: expected to become dominant from FY2027 if the new lease commences. | Derived from the above |
Value-chain position, customers and end-markets
Software services: The company acts as a small offshore delivery vendor. It sits at the bottom of the IT services value chain, as a subcontractor or niche vendor to mid-sized US enterprises. It has no disclosed platform IP of scale. Named clients are not publicly disclosed.
Real estate: The company is a land-owner and co-developer through a joint development agreement (JDA), where the developer builds and the parties share the built-up area. Its customers are office occupiers in Hyderabad's Financial District, which is a global capability centre (GCC) corridor.
Education: Customers are students and parents in India (CBSE, ICSE, IGCSE, IB curricula and IIT-JEE/NEET preparation) and, aspirationally, global markets.
Healthcare (historic): Customers were independent retail pharmacies (India has 8 lakh+ standalone medical stores, per Business India), stockists, virtual care providers, and US pharmacy businesses.
Independent characterisation
On the evidence, Athena Global is no longer primarily an IT services company. The key facts are:
-
Consolidated operating revenue has fallen from about ₹26 Cr in FY2020–21 to ₹11.2 Cr in FY2026.
-
Consolidated operating losses were recorded in each of FY2022–FY2026.
-
About ₹200–280 Cr of balance-sheet value sits in investment property.
The company's value, its debt service and its equity story now all depend on the Manikonda property. The software business is too small to cover finance costs, which were ₹17 Cr in FY2026 (Screener) against operating revenue of ₹11.2 Cr. The healthcare and ed-tech subsidiaries have been loss-making or marginal capital sinks: the investment in Medley carried at ₹3,360.94 lakh (FY2021-22 AR) was ultimately sold for ₹125.34 lakh in March 2026. Investors should analyse Athena as a leveraged real estate holding company with an option on a small tech services business, not as an IT services compounder.
Strategy
Stated strategy themes (FY2023-24 AR MD&A, paraphrased)
-
Remain a relevant, skilled and strategic partner to customers as Indian IT moderates.
-
Invest in talent development, better infrastructure, and design-thinking capabilities across the organisation.
-
Keep strategic mergers and acquisitions on the radar to add leverage to growth.
-
Grow consolidated income through the start-up subsidiaries:
-
Tutoroot, positioned as differentiated by its teaching approach.
-
MedleyMed, positioned by management as a customisable integrated pharmacy and telehealth platform with global ambitions.
-
-
Management states confidence in new projects but provides no quantified targets.
-
The FY2024 Schedule V disclosure attributes losses to higher manpower and administrative costs taken on in anticipation of contracts still under discussion, without matching revenue.
No investor day has been held. There are no earnings calls or investor presentations on record (0 analysts cover the stock per S&P).
Initiatives in the last 24 months (Oct 2024 – Oct 2026)
| Date | Initiative | Type | Target / scale | Status | Source |
|---|---|---|---|---|---|
| Aug 2024 | ₹125 Cr secured listed NCD programme (refinance, repay unsecured loans, working capital) | Capital structure | ₹125 Cr | Superseded | Equity Bulls |
| Late 2024 – early 2025 | Proposed ₹150 Cr NCDs rated by Infomerics; about ₹40 Cr to repay debt; about ₹30 Cr interest reserve | Capital structure | ₹150 Cr | Withdrawn 25 Feb 2025 | Infomerics PR; Reuters |
| 1 Oct 2024 | MD remuneration raised to ₹96 lakh p.a. | Governance / cost | +₹36 lakh p.a. | Approved at 32nd AGM | FY2023-24 AR |
| 25 Feb 2025 | Sale / lease of 1,50,000 sq ft of property | Asset monetisation | 1.5 lakh sq ft | Partly executed (FY2026 derecognition gain; Sep 2026 lease) | Reuters |
| Aug 2025 | Conversion of 6.5 lakh promoter warrants at ₹87 | Equity infusion | about ₹5.66 Cr total (derived) | Done | Screener |
| Mar–Apr 2026 | 7 lakh promoter warrants at ₹84 | Equity infusion | ₹5.88 Cr total; ₹1.47 Cr received | Allotted 13 Apr 2026 | HDFC Sky |
| 31 Mar 2026 | Healthcare restructuring (MedleyMed Healthcare acquisition / Medley Medical divestment) | Portfolio | ₹10,000 / ₹1.25 Cr | Completed | IndiaIPO |
| 30 May 2026 | Investment of up to ₹50 Cr in OCDs of Medley Medical Solutions and Tutoroot | Capital allocation | ₹50 Cr | Approved; deployment not disclosed | Whalesbook |
| 18 Sep 2026 | 5-year lease of 1,19,526 sq ft at ₹11.19 Cr per year from 27 Nov 2026 | Real estate monetisation | about ₹56 Cr gross over 5 years (derived, before escalations) | Contracted | BSE Reg. 30 |
| Ongoing | AI-led repositioning of the software brand (website titled "Custom AI Solutions & Automation Services") | Brand / offering | Not quantified | Ongoing | athenagt.com |
Other commitments and guidance
ESG / sustainability: none disclosed. CSR is not applicable.
Cost programmes: none formally announced.
Medium-term financial targets / guidance: none disclosed.
Analytical observation: committing up to ₹50 Cr to OCDs of loss-making subsidiaries is very large relative to market capitalisation (about ₹72–75 Cr) and FY2026 equity (₹142 Cr). It would compete with debt reduction for any cash freed by property monetisation. This is the single most important capital-allocation decision to monitor.
Products & Services
Pricing models are not publicly disclosed for any line unless stated.
Software Services segment
| Offering | Description / capabilities | Target customer | Launch / latest year | Flagship / named | Source |
|---|---|---|---|---|---|
| Software application development | Custom application builds and re-engineering; offshore/onsite model through the Hyderabad EOU and US branch | Mid-size enterprises, mainly US | Core since 1990s; current | None named | FY2023-24 AR MD&A |
| Product engineering | Building "future-proof" products for clients | ISVs, enterprises | Current | — | FY2023-24 AR |
| QA & testing | Functional/production QA; "custodian of your production environment" positioning | Enterprises | Current | — | FY2023-24 AR |
| Digital transformation | Cloud, analytics, process digitisation | Enterprises | Current | — | AR; LinkedIn |
| AI services | Real-time customer interaction, predictive and diagnostic applications | Enterprises | Current | — | AR |
| Blockchain | "Internet of Value" solutions on Ethereum and Hyperledger | Enterprises | Current | — | AR; LinkedIn |
| Data science / analytics | Model design and actionable intelligence | Enterprises | Current | — | AR |
| IoT solutions | Customer engagement through connected devices | Enterprises | Current | — | AR |
| RPA, chatbots and voicebots | Business process automation powered by cognitive technologies | Enterprises | Current | — | AR |
| Enterprise information management / integration / data warehousing | EIM, EAI and DW services | Enterprises | Current | — | AR (Opportunities section) |
| Digitalisation of records / OCR | Document digitisation and OCR | Enterprises, government | Current | — | S&P profile |
| GRC consulting | Governance, risk and compliance advisory | Enterprises | Current | — | S&P profile |
| Voice / non-voice technical support | IT-enabled support (ITES) | Enterprises | Current | — | S&P; Screener |
| Business process optimisation | Process consulting | Enterprises | Current | — | S&P profile |
| Advisory, structuring, sustainability consulting | Consulting | Corporates | Current | — | S&P profile |
| Legacy branded products | VJ STS, VJPDS (domestic installations, mid-1990s) | Indian corporates | 1995-96 | VJ STS, VJPDS | IIFL summary |
| Legacy education services | IT training centres (9 by FY1996) | Students | 1990s; discontinued (presumed) | — | IIFL summary |
Real Estate segment
| Asset / offering | Description | Size / value | Status | Source |
|---|---|---|---|---|
| Manikonda Financial District IT/SEZ development | 5 acres at Sy. No. 203 (part), Manikonda Jagir, Rajendra Nagar Mandal, Ranga Reddy District; developed through a JDA with Phoenix Tech Zone Pvt Ltd | Company's share of buildings fair-valued at ₹23,900 lakh (FY2024) | Completion approval received FY2024 | FY2023-24 AR |
| Sale/lease programme | Board approval to sell/lease 1,50,000 sq ft | 1,50,000 sq ft | Approved 25 Feb 2025 | Reuters |
| Partial derecognition | Portion of investment property derecognised, gain ₹23.40 Cr | — | Q3 FY2026 | FY2026 results coverage |
| Lease contract | 1,19,526 sq ft leased for 5 years at ₹11.19 Cr per year (about ₹78 per sq ft per month, derived) | 1,19,526 sq ft | Commences 27 Nov 2026 | BSE Reg. 30, 18 Sep 2026 |
Online Education segment (Tutoroot Technologies)
| Offering | Description | Target customer | Year | Source |
|---|---|---|---|---|
| "LEARN" platform | In-house platform with live interactive classes, live simulations, adaptive assessments, subject demo videos and courseware | K-12 and exam aspirants | Launched about 2021 (company founded 2019) | Business News Today; Glassdoor |
| Personalised tuitions | 1:1 and small-group live online tutoring with part-time faculty (e.g., CBSE computer science) | CBSE / ICSE / IGCSE / IB students | Current | Glassdoor job listing |
| Competitive exam preparation | IIT-JEE and NEET programmes | Grade 11–12 students | Current | Launch coverage |
| Classroom teaching | Hybrid / classroom programmes | Students | Current | Glassdoor |
Healthcare platforms (MedleyMed — restructured March 2026)
| Offering | Description | Target customer | Year | Source |
|---|---|---|---|---|
| B2B pharmacy aggregation / replenishment | Aggregator for thousands of small pharmacies; claimed 95–98%+ fulfilment backed by its backend network; loyalty rewards | Independent pharmacies (India) | c. 2017–2021 | Business India feature |
| Pharmacy franchise model | Franchise network under the MedleyMed brand | Pharmacy entrepreneurs | Announced 2021 | BioSpectrum |
| Pharmacy ERP (SaaS) | Backend ERP for pharmacy operations, inventory and contracting | Pharmacies | Current at the time | Business India; YourStory |
| Telemedicine SaaS / virtual clinic | Online consultation, diagnostics, built-in EHR, digital prescribing | Virtual care providers, patients | 2,021 | YourStory; BioSpectrum |
| Local street clinics | Physical clinics building on the platform | Patients | c. 2022 | Business India |
| US digital health suite | Platform solutions for US pharmacy and virtual-care businesses (offices in Hyderabad and Austin, Texas) | US pharmacies, virtual care companies | Sep 2021 | BioSpectrum; YourStory |
| Online trade of pharma products | Trading of pharmaceutical products (segment 4) | Pharmacies / consumers | FY2023–FY2025 | FY2023-24 AR; IndiaIPO |
It does not sit easily with Medley's FY2025 revenue of ₹2.71 lakh.
Financial Narrative
Sources: Screener (C-MOTS), StockAnalysis (S&P), Business Standard / Capital Market, ARs as cited. Figures are rounded to ₹ Cr. FY2026 includes the ₹32.36 Cr exceptional loss on the Medley divestment and a ₹23.40 Cr property gain in other income.
Income statement (₹ Cr)
Notes:
-
FY2025 PBT of ₹(1,922.64) lakh is from the FY2024-25 Directors' Report.
-
FY2026 PBT is the sum of reported quarterly PBT: -4.35 (Q1), -6.50 (Q2), 9.32 (Q3), -37.20 (Q4).
-
FY2026 reported diluted EPS is not captured in sources reviewed; the derived figure assumes 14.05m shares to Aug 2025 and 14.70m thereafter.
-
Screener shows FY2026 PAT of -13 because it excludes the exceptional item. The reported consolidated loss of ₹45.68 Cr (₹4,567.62 lakh) is confirmed by ScanX and Whalesbook coverage of the 30 May 2026 results.
-
Diluted EPS for earlier years is the same as basic or is not separately disclosed.
-
The company has never declared a dividend since inception (FY2023-24 AR).
Margin profile (%)
Revenue CAGR FY2022–FY2026 (derived): -13.6% per year. Screener reports a 5-year sales CAGR of -16% and a 3-year CAGR of -2%.
Commentary. The P&L has three regimes:
FY2022–FY2023 — collapse: Revenue fell from ₹20.1 Cr to ₹12.0 Cr. Expense levels held at ₹27–28 Cr as the company kept funding Medley and Tutoroot build-outs, pushing operating losses to ₹15 Cr.
FY2024 — accounting windfall: Completion of the Manikonda JDA allowed the company to recognise the buildings at fair value. This added ₹235.94 Cr to other income and turned a structurally loss-making year into a ₹205 Cr profit. The gain was non-cash and is not repeatable. Note also the FY2024 Q4 expense spike (₹16.93 Cr in the quarter vs ₹4–7 Cr run-rate), which management did not explain in available extracts.
- FY2025–FY2026 — reversion to losses, now with higher finance costs. FY2025 showed some operating discipline (OPM -46%, Q3 FY2025 near break-even at -0.72%). FY2026 regressed: revenue fell 28% and Q3 FY2026 expenses jumped to ₹8.93 Cr. Marketsmojo reports employee cost at 82.65% of revenue in Q4 FY2026. Finance costs reached ₹17 Cr, more than the entire revenue base.
Quarterly trend (₹ Cr, consolidated)
Sources: Screener quarterly table; Q4 FY2026 PBT and net profit (including exceptional item) from Marketsmojo / Kotak Neo / Whalesbook; Q1 FY2027 from Capital Market (JM Financial), 15 Aug 2026.
Q1 FY2027 is the best operating quarter in two years. Sales rose 57% YoY to ₹4.75 Cr and the operating margin was close to break-even (-0.84% vs -46.03%). This is an early sign that the cost base has been reset.
Balance sheet (₹ Cr, consolidated, 31 March)
Notes:
-
Infomerics cites total debt of about ₹85.39 Cr at 31 March 2024, consistent with Screener's ₹86 Cr.
-
Net debt approximately equals gross debt; given small annual net cash flows (FY2026 net cash flow +₹9 Cr), cash is likely in single-digit ₹ Cr (inference).
-
Working capital is negative on Screener's working-capital-days metric (-516 days in FY2026), reflecting large other liabilities against small current assets.
Commentary.
-
The balance sheet was transformed in FY2024 when investment property moved from CWIP/land at cost to fair value. Equity went from negative ₹11 Cr to ₹200 Cr. Since then, equity has fallen through losses (₹200 Cr → ₹142 Cr in two years) while borrowings rose 51% (₹86 Cr → ₹130 Cr).
-
The fall in fixed assets in FY2026 (₹282 Cr → ₹203 Cr), the ₹23.40 Cr derecognition gain, and the +₹48 Cr investing cash flow together suggest a portion of the property was sold or transferred in FY2026. Despite that inflow, gross debt still rose by ₹30 Cr.
-
The jump in other assets to ₹66 Cr may reflect receivables from the property transaction and the Medley consideration. Screener shows debtor days of 202 in FY2026.
Cash flow (₹ Cr, consolidated)
The two data vendors disagree on FY2025 operating cash flow (₹13 Cr vs ₹9.61 Cr); both are shown. Capex as a separate line is not captured. FCF is as computed by Screener (OCF less capex).
Commentary. Positive operating cash flow in FY2024–FY2025 despite operating losses is consistent with working-capital inflows such as advances or related-party payables. The -₹57 Cr operating outflow in FY2026, against +₹48 Cr from investing, suggests the property transaction proceeds were classified in investing activities while working capital unwound (for example, settlement of liabilities, which fell from ₹62 Cr to ₹41 Cr). The -₹62 Cr FY2026 FCF was funded by ₹18 Cr of financing inflow (debt plus warrant money) and property proceeds.
Ratios (derived from the tables above unless stated)
Notes:
-
FY2023 debt-to-equity is not meaningful because equity was negative.
-
FY2026 interest coverage excludes the exceptional item; FY2024 coverage is inflated by the fair-value gain.
-
The FY2023-24 AR key-ratio disclosure reports standalone interest coverage of 20.72x for FY2024 vs -0.46x for FY2023, attributing the change to the fair-value gain.
-
Net debt/EBITDA is not meaningful because EBITDA was negative in every year.
-
The current ratio is not captured in the sources reviewed.
Interpretation.
-
Excluding the FY2024 gain, the company has not earned its interest bill in any of the last five years.
-
At FY2026 levels (₹130 Cr debt, ₹17 Cr finance cost), the implied cost of debt is about 13% (derived). This is consistent with non-bank or related-party funding: promoter and Vishwashree Enterprises loans are disclosed in FY2024 related-party transactions.
-
The new lease (₹11.19 Cr per year) would cover roughly two-thirds of the FY2026 finance cost before any operating expenses. That illustrates both its importance and its insufficiency on its own.
Standalone summary (₹ Cr)
Sources: FY2021-22, FY2023-24 and FY2024-25 ARs; Whalesbook / ScanX for FY2026. FY2026 standalone other income and PBT are not captured. Q3 FY2026 standalone profit was ₹348.36 lakh on revenue of ₹223.76 lakh (ScanX).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Relationship | Country | Business | Status / notes | Source |
|---|---|---|---|---|---|
Athena Global Technologies Ltd | Listed parent | India | Software services; real estate (investment property) | BSE 517429 | AR |
Tutoroot Technologies Pvt Ltd | Wholly owned subsidiary | India | Online education | Investment ₹1,457.80 lakh (FY2022 AR); FY2024 turnover ₹36.01 lakh, PBT ₹4.11 lakh (AOC-1) | FY2021-22 AR; FY2023-24 AR |
Athena Global Technologies, Inc. | Wholly owned subsidiary | USA | Software services / onsite delivery | FY2024 AOC-1: turnover 354.01, PBT 48.52 (reported in the USD-entity column; unit presentation in the AR is ambiguous) | FY2023-24 AR |
Athena Global Technologies UK Ltd | Wholly owned subsidiary | UK | Software development | Incorporated 30 May 2024; "yet to commence operations" per FY2024 AOC-1 | BSE filing; FY2023-24 AR |
MedleyMed Healthcare Solutions Pvt Ltd (CIN U24239TG2019PTC136763) | 100% acquired 31 Mar 2026 for ₹10,000 (previously a step-down subsidiary through Medley) | India | Healthcare / pharma trading | Turnover ₹299.95 lakh (FY23), ₹299.75 lakh (FY24), ₹44.18 lakh (FY25) | IndiaIPO |
Medley Medical Solutions Pvt Ltd | Former subsidiary; entire stake divested 31 Mar 2026 to MedleyMed Healthcare Solutions for ₹1,25,33,689 | India | Pharmacy platform, telemedicine | FY2024 turnover ₹92.37 lakh, PBT ₹(374.16) lakh (AOC-1) | IndiaIPO; FY2023-24 AR |
MedleyMed Logistics Pvt Ltd | Step-down subsidiary (FY2024) | India | Logistics for MedleyMed | Current status not disclosed | FY2023-24 AR (AOC-2) |
Vishwashree Enterprises Pvt Ltd | Associate enterprise in which directors have substantial interest (not a subsidiary) | India | Related-party lender | Loans received ₹706.75 lakh, repaid ₹391.15 lakh in FY2024 | FY2023-24 AR |
Revenue by Segment and Revenue by Segment (%)
| Metric (INR Cr) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Consolidated revenue from operations | 20.11 | 12.02 | 13.78 | 15.62 | 11.20 |
Standalone revenue from operations (software + real estate) | 17.83 | 9.80 | 9.71 | 12.18 | 8.06 |
Subsidiaries contribution derived (consolidated minus standalone, before eliminations) | 2.28 | 2.22 | 4.07 | 3.44 | 3.14 |
Standalone share of consolidated revenue % derived | 88.7 | 81.5 | 70.5 | 78.0 | 72.0 |
Standalone revenue YoY growth % derived | — | -45.0 | -0.9 | 25.4 | -33.8 |
Revenue by Segment (x) and Results by Segment
| Metric (INR Lakh) | FY2024 | FY2025 |
|---|---|---|
Medley Medical turnover (AOC-1) | 92.37 | — |
Medley Medical revenue from operations (Directors' Report extract) | 23.82 | 2.71 |
Medley Medical net profit (Directors' Report extract) | -374.86 | -301.71 |
Tutoroot turnover (AOC-1) | 36.01 | — |
Tutoroot PBT (AOC-1) | 4.11 | — |
Income Statement and Per-Share Data
| Metric (INR Cr) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations | 20.11 | 12.02 | 13.78 | 15.62 | 11.20 |
Gross profit (S&P definition) | 2.38 | -4.15 | -0.95 | 2.40 | 1.74 |
Total operating expenses (Screener) | 28 | 27 | 33 | 23 | 24 |
EBITDA excluding other income (Screener operating profit) | -8 | -15 | -19 | -7 | -13 |
Other income | 9 | 1 | 237 | 1 | 25 |
Finance cost | 9 | 7 | 11 | 12 | 17 |
Depreciation | 0 | 1 | 0 | 1 | 2 |
Exceptional items | 0 | 0 | 0 | 0 | -32.36 |
Profit before tax (reported) | -8 | -22.65 | 205.82 | -19.23 | -38.73 |
Net profit (reported) | -8.07 | -22.03 | 205.10 | -20.14 | -45.68 |
EPS basic ₹ (reported) | -5.80 | -15.65 | 146.19 | -14.16 | — |
EPS ₹ derived on about 14.5m weighted shares | — | — | — | — | -31.5 |
Dividend per share ₹ | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin derived | 11.8 | -34.5 | -6.9 | 15.4 | 15.5 |
EBITDA margin excluding other income (Screener OPM) | -38 | -127 | -140 | -46 | -115 |
Net margin derived | -40.1 | -183.3 | 1,488.4 | -128.9 | -407.9 |
Revenue growth YoY derived | -22.8 | -40.2 | 14.6 | 13.4 | -28.3 |
Income Statement
| Metric (INR Cr) | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|---|---|---|---|---|
Sales | 4.17 | 4.37 | 4.19 | 2.89 | 3.02 | 2.57 | 2.21 | 3.40 | 4.75 |
Operating profit | -2.17 | -0.85 | -0.03 | -4.19 | -1.39 | -3.56 | -6.72 | -1.17 | -0.04 |
Other income | 0.03 | 0.18 | 0.01 | 0.45 | 0.02 | 0.34 | 23.52 | 0.71 | 0.03 |
Interest | 2.69 | 2.80 | 3.66 | 2.90 | 2.63 | 2.89 | 7.10 | 3.97 | 2.71 |
PBT | -4.90 | -3.50 | -3.84 | -6.99 | -4.35 | -6.50 | 9.32 | -37.20 | -3.13 |
Net profit (reported) | -4.74 | -4.69 | -3.84 | -6.88 | -4.34 | -6.37 | 1.14 | -36.11 | -3.15 |
Balance Sheet
| Metric (INR Cr) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets | 77 | 95 | 325 | 342 | 312 |
Fixed assets incl. investment property | 39 | 38 | 273 | 282 | 203 |
Capital work in progress | 19 | 25 | 32 | 40 | 42 |
Investments | 0 | 6 | 3 | 0 | 0 |
Other assets (incl. receivables and cash) | 19 | 26 | 17 | 20 | 66 |
Equity share capital | 13 | 13 | 14 | 14 | 15 |
Reserves | -5 | -24 | 186 | 166 | 127 |
Total equity derived | 8 | -11 | 200 | 180 | 142 |
Total borrowings | 45 | 74 | 86 | 100 | 130 |
Other liabilities | 24 | 31 | 39 | 62 | 41 |
Cash Flow
| Metric (INR Cr) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (Screener) | -4 | -21 | 12 | 13 | -57 |
Operating cash flow (Torus / reported variant) | -4.14 | -20.75 | 11.80 | 9.61 | — |
Investing cash flow | -9 | -13 | -5 | -4 | 48 |
Financing cash flow | 12 | 35 | -8 | -9 | 18 |
Free cash flow (Screener) | -13 | -27 | 4 | 7 | -62 |
Dividends paid | 0 | 0 | 0 | 0 | 0 |
Buybacks | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE % (net profit / average equity) | — | — | 422.4 | -10.6 | -28.4 |
ROE % (Screener, last year) | — | — | — | — | -27.7 |
ROA % (net profit / year-end total assets) | -10.5 | -23.2 | 63.1 | -5.9 | -14.6 |
ROCE % (Screener) | 3 | -26 | 124 | -3 | -5 |
ROIC % (S&P / MarketInOut, latest TTM) | — | — | — | — | -3.52 |
Debt to equity (x) | 5.63 | — | 0.43 | 0.56 | 0.92 |
Interest coverage (EBIT incl. other income / interest, x) | 0.1 | -2.1 | 19.8 | -0.6 | 0.6 |
Asset turnover (revenue / total assets, x) | 0.26 | 0.13 | 0.04 | 0.05 | 0.04 |
Debtor days (Screener) | 136 | 237 | 69 | 90 | 202 |
Cash conversion cycle days (Screener) | 70 | 162 | -133 | 90 | 202 |
Income Statement (Annual)
| Metric (INR Cr) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Standalone revenue from operations | 17.83 | 9.80 | 9.71 | 12.18 | 8.06 |
Standalone other income | 9.20 | 1.75 | 238.84 | 2.48 | — |
Standalone PBT | — | -9.56 | 214.42 | -13.23 | — |
Standalone net profit | — | -8.90 | 213.74 | -14.12 | -39.70 |
Results by Region
| Metric (INR Lakh) | FY2019 | FY2020 | FY2023 | FY2024 |
|---|---|---|---|---|
Foreign exchange earnings | 820.33 | 1,292.57 | 687.23 | 817.70 |
Foreign exchange outgo | 247.85 | 441.59 | 272.68 | 272.75 |
Net FX earnings derived | 572.48 | 850.98 | 414.55 | 544.95 |
Revenue by Region (%)
| Metric (%) | FY2023 | FY2024 |
|---|---|---|
FX earnings as % of standalone revenue derived | 70.1 | 84.2 |
Domestic share of standalone revenue derived | 29.9 | 15.8 |
Valuation Snapshot
| Metric | Value | Source |
|---|---|---|
Last close | ₹51.20 (19 Oct 2026) | Screener |
52-week range | ₹49.4 – ₹92.4 | Screener |
1-year return | -34% | Screener |
3-year price CAGR | -13% | Screener |
5-year price CAGR | -11% | Screener |
10-year price CAGR | +3% | Screener |
5-year high / low | ₹129.89 / ₹30.00 | HDFC Sky (Apr 2026) |
Per-Share Data
| Metric (₹ per share) | FY2025 | FY2026 |
|---|---|---|
Book value per share consolidated derived (equity / shares) | 128 | 97 |
Valuation Multiples
| Multiple | Athena Global | Kellton Tech | Saksoft | Mindteck |
|---|---|---|---|---|
P/E (TTM) | Not meaningful (TTM net loss about ₹44.5 Cr, derived) | 60.2 (Screener snapshot; date of snapshot uncertain) | About 14 (derived: about ₹1,899 Cr market cap / ₹133 Cr PAT; snapshot date uncertain) | About 19.9 (Aug 2026) |
P/B | 0.51 | 3.11 (snapshot) | Not captured | Not captured |
EV/EBITDA | Not meaningful (negative EBITDA) | Not captured | Not captured | Not captured |
EV/Sales (TTM) | About 15.9x derived (EV about ₹205 Cr = ₹75 Cr market cap + ₹130 Cr gross debt, cash not deducted; TTM sales ₹12.93 Cr). MarketInOut shows 14.33x. | Not captured | Not captured | Not captured |
Capital Markets
| Item | Status | Source |
|---|---|---|
Analyst consensus | None — 0 analysts cover the stock | S&P via Simply Wall St |
Algorithmic ratings | Marketsmojo "Strong Sell" (Jun 2026) | Marketsmojo |
Dividend history | No dividend ever declared | FY2023-24 AR |
Dividend policy | Not disclosed beyond "inadequacy of profit" | AR |
Moody's / S&P / Fitch | Not rated | — |
Domestic rating | Infomerics rated the proposed ₹150 Cr NCDs (grade not captured); issue withdrawn | BSE / Infomerics |
Lender identity | Not publicly disclosed beyond related-party loans (M. Satyendra, M. Sunitha, Vishwashree Enterprises) | FY2023-24 AR |
Implied cost of debt | About 13% (FY2026 finance cost ₹17 Cr / borrowings ₹130 Cr, derived) | Screener |
Analyst Conclusions
Management guidance and consensus
Management guidance: none quantified. The MD&A expresses generic confidence in winning new projects.
Consensus: none (no coverage).
Data-implied run-rate (analyst scenario, not guidance)
-
Software and other operating revenue at the Q1 FY2027 level: about ₹4.75 Cr per quarter, or about ₹19 Cr annualised.
-
Lease income: ₹11.19 Cr per year from 27 Nov 2026, or about ₹4 Cr in FY2027 and a full ₹11.19 Cr from FY2028.
-
If operating costs stay near Q1 FY2027 levels (about ₹4.8 Cr per quarter) and finance cost stays at about ₹11–17 Cr, FY2028 could be near PBT break-even. That outcome assumes no further subsidiary losses or write-downs.
Bull case
-
The lease transforms the revenue mix. ₹11.19 Cr of annual contracted rent from 27 Nov 2026, on a 5-year tenor, roughly doubles recurring revenue against FY2026's ₹11.2 Cr. Rental income carries high margins.
-
Deep asset discount with a visible catalyst path. P/B is about 0.5x. Further leasing or sale of the remaining approved inventory, in a Hyderabad market absorbing a record 13+ mn sq ft in nine months, could crystallise value and reduce the ₹130 Cr of debt.
-
The operating cost base has been reset. Q1 FY2027 OPM of -0.84% is the best in the visible quarterly series. Sales grew 57% YoY. The promoter keeps injecting equity at ₹84–87, a price above the current ₹51.
Bear case
-
Leverage exceeds operating capacity. Interest of ₹17 Cr against ₹11 Cr of revenue, debt up ₹44 Cr in two years, and a failed NCD raise. Lease cash may service debt rather than create equity value.
-
Capital allocation has repeatedly destroyed value, and may again. Medley's ₹33.6 Cr investment was sold intra-group for ₹1.25 Cr. The new ₹50 Cr OCD approval targets the same subsidiaries. Equity fell from ₹200 Cr to ₹142 Cr in two years.
-
Governance and disclosure quality are weak. Related-party loans and sale, CMD duality, short independent director terms, AR inconsistencies, no investor communication, and zero institutional ownership. All of this justifies a structural discount that may not close.
Catalysts and monitorables (next 12 months)
| # | Item | Timing | What to watch |
|---|---|---|---|
| 1 | Q2 FY2027 results | About mid-Nov 2026 | Whether Q1's near-break-even operating profit holds; finance cost trend |
| 2 | Lease commencement | 27 Nov 2026 | Rent recognition in Q3/Q4 FY2027; lessee identity and security deposit |
| 3 | OCD deployment | Any time | Amount actually invested in Medley / Tutoroot out of the ₹50 Cr approved; terms and coupon |
| 4 | Debt | Quarterly | Any refinancing, repayment, or lender disclosure; trend in the ₹130 Cr borrowings |
| 5 | Warrant conversion | By about Oct 2027 (18-month SEBI limit, derived) | Conversion of 7 lakh warrants (balance about ₹4.41 Cr, derived) — a signal of promoter conviction |
| 6 | Remaining property inventory | FY2027 | Further leases or sales out of the 1.5 lakh sq ft approved in Feb 2025 |
| 7 | MD re-appointment / governance | FY2027 | MD term expired 13 May 2026 — confirm re-appointment and any independent director refresh |
| 8 | FY2026 AR details | Available | Segment results, debt maturities, lessee/receivable disclosures, auditor opinion type |
| 9 | Q4 FY2027 / FY2027 results | May 2027 | First full-quarter rent; any fair-value movements on the property |
Concluding analyst verdict
Athena Global Technologies should not be analysed as the IT services company its name suggests. Over five years:
-
Consolidated operating revenue has roughly halved, to ₹11.2 Cr.
-
Operating losses have been continuous.
-
The headline profits of FY2024 (₹205 Cr) and Q3 FY2026 (₹1.14 Cr) were produced by non-cash fair-value and derecognition gains on a single real estate asset in Hyderabad's Financial District.
That asset is the company. It supports roughly ₹203 Cr of fixed assets, the ₹142 Cr equity base, and the ₹130 Cr of high-cost debt.
The September 2026 lease of 1,19,526 sq ft at ₹11.19 Cr a year is the most important positive development in the company's recent history. It arrives during an exceptional Hyderabad leasing cycle. Q1 FY2027 also offered the first evidence that the operating cost base has been reset. Together these make a path to near-break-even plausible within about 18 months, and the stock's 0.5x price-to-book discount gives room for re-rating if that path is executed.
Against this, minority shareholders face three structural problems:
-
Leverage is large relative to cash generation.
-
Capital allocation has repeatedly favoured promoter-incubated subsidiaries at shareholders' expense, most recently through a related-party Medley transfer at a ₹32 Cr loss and a fresh ₹50 Cr OCD approval.
-
Governance and disclosure standards are well below institutional norms: no analyst coverage, no investor calls, inconsistent AR disclosures and no institutional shareholders.
Verdict. This is a speculative, special-situation real estate monetisation story with high governance risk. The decisive monitorables over the next two to four quarters are:
-
Lease cash actually reaching the P&L from Q3 FY2027.
-
Debt reduction rather than OCD deployment.
-
Conversion of the outstanding promoter warrants.
Absent clear progress on all three, the discount to book is likely to persist or widen.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles / background | Education | Source |
|---|---|---|---|---|---|
M. Satyendra (Satish Manchala) | Chairman & Managing Director (DIN 01843557); promoter | — | 3+ decades in industry; leads international operations; founder of MedleyMed and Tutoroot | Management graduate | FY2023-24 AR |
Sudeep Nadkarni | Chief Executive Officer | Since 1 Aug 2023 (per MarketScreener) | Chief Revenue Officer (GBR) at 3i Infotech (Nov 2022–2023); earlier at Kanbay Inc. (business intelligence lead); also listed by S&P as CEO of ALTAFID Inc. | MBA, Kellogg School of Management | MarketScreener; Simply Wall St |
Julakanti Venkata Ramakrishna | Chief Financial Officer | About 6 years (S&P) | — | — | FY2023-24 AR; Simply Wall St |
Divya Agrawal | Company Secretary & Compliance Officer (FY2022–FY2024 filings) | Through at least FY2024 | Membership No. 48143 | CS | BSE filings |
Gayathri Prithviraj | Company Secretary & Compliance Officer (per S&P, under 1 year) | 2025–26 | — | CS | Simply Wall St |
Rajesh Patil | Chief Operating Officer | — | — | — | Simply Wall St |
Abdul Ghalib | Senior Vice President | — | — | — | Simply Wall St |
Phaniraj Uppendra Gollapudi | SVP, Engineering Services | — | — | — | Simply Wall St |
“—” = not publicly disclosed.
Board of Directors
| Name | Category | Appointed | Committees | Notes |
|---|---|---|---|---|
M. Satyendra | Promoter, Chairman & MD (executive) | Inception | — | Spouse of M. Sunitha |
M. Sunitha (Sunitha Manchala) | Non-executive, promoter, woman director (DIN 06741426) | 6 Nov 2014 | — | Born 6 Sep 1974; B.A., B.Com, LLB; finance and administration expertise; holds 16,41,326 shares; re-appointed at the 34th AGM (30 Sep 2026) |
Avinash Vashistha | Non-executive director | — | Audit / NRC / SRC member until 14 Nov 2023 | Classified as "Director" in corporate information but "Non-Executive Independent Director" in the governance table — internal inconsistency. Holds 2,00,000 shares; Vashistha family members (Garima 2.61%, Ankita 1.21%) also hold stakes. |
Ramesh Babu Nemani | Independent director | — | Chairman of Audit, NRC and SRC from 8 May 2023 | — |
Nukala Ashwanth | Independent director (DIN 09719259) | 1 Sep 2022; re-appointed for 1 year from the 32nd AGM (Sep 2024) | Member of all 3 committees | Born 27 Jul 1988 |
Maddi Venkata Sudarsan | Independent director (DIN 00988521) | 2 Aug 2023 for 2 years | Member of all 3 committees from 14 Nov 2023 | — |
Prudvi Raju Manthena | Independent director (former) | — | Former Audit Committee Chair | Died 6 May 2023 |
“—” = not publicly disclosed.
Executive Leadership Team — M. Satyendra
| Name | Role | Salary / remuneration (INR Lakh) | Stock | Total (INR Lakh) |
|---|---|---|---|---|
M. Satyendra | CMD | 58.40 | Nil disclosed | 58.40 |
J.V. Ramakrishna | CFO | 11.54 | ESOP eligibility not disclosed | 11.54 |
Divya Agrawal | CS | 10.66 | — | 10.66 |
Major Shareholders
| Holder | Category | Shares | % of 1,47,00,000 | Source |
|---|---|---|---|---|
M. Satyendra | Promoter | 69,90,612 | 47.52 | Bajaj Finserv (BSE shareholding) |
Sunitha Manchala | Promoter | 16,41,326 | 11.16 | Same |
Karthikeya Manchala | Promoter group | 6,50,000 (+7,00,000 warrants) | 4.42 | Same; BSE |
Garima Vashistha | Public | 3,83,413 | 2.61 | Same |
Vijay Acharya | Public | 2,39,079 | 1.63 | Same |
Aluri Srinivasa Rao | Public | 2,17,684 | 1.48 | Same |
Avinash Vashistha | Public (director) | 2,00,000 | 1.36 | Same |
Ankita Vashistha | Public | 1,78,228 | 1.21 | Same |
Vipul Premchand | Public | 1,74,911 | 1.19 | Same |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Type | Relative positioning vs Athena |
|---|---|---|---|
Software services / digital transformation | Kellton Tech Solutions (Hyderabad) | Listed small-cap | About 100x Athena's revenue; profitable; same city and similar digital/AI pitch |
Software services | Saksoft | Listed small-cap | ₹1,007 Cr revenue, about 20% EBITDA margin; US/UK mid-market focus |
Software / engineering services | Mindteck (India) | Listed micro/small-cap | ₹407 Cr revenue; profitable; niche engineering verticals |
QA & testing | Cigniti Technologies (Hyderabad; now part of the Coforge group) | Listed specialist | Global QA leader among Indian mid-tiers; Athena's QA offering is sub-scale by comparison |
IT services (micro-cap peers) | AAA Technologies, Sylph Technologies | Listed micro-caps | Comparable scale; listed by Simply Wall St in the same peer screens |
Offshore development (private) | NeoSOFT Technologies, Alphamu Software, Empiezo IT Solutions | Private | Named by CB Insights as Athena competitors |
IT services (large) | Tech Mahindra, EXL, Quantiphi | Large / mid | Named as competitors by TheCompanyCheck; not realistic head-to-head peers |
Online education | PhysicsWallah, Vedantu, BYJU'S, Unacademy | Ed-tech platforms | Orders of magnitude larger; Tutoroot is sub-scale |
E-pharmacy / pharmacy SaaS | Tata 1mg, PharmEasy (API Holdings), Apollo 24/7, Netmeds | Platforms | MedleyMed is sub-scale; healthcare exit effectively executed Mar 2026 |
Hyderabad office real estate | RMZ, Salarpuria Sattva, Phoenix Group, office REITs with Hyderabad assets | Developers / landlords | Athena is a single-asset landlord and price-taker in a deep market |
Peer Comparison FY2026
| Metric | Athena Global | Kellton Tech | Saksoft | Mindteck |
|---|---|---|---|---|
Revenue (INR Cr) | 11.20 | 1225.36 (total revenue) | 1,007.19 | 407.30 |
Revenue growth YoY % | -28.3 | 11.4 | 14 | -4.0 |
Operating / EBITDA margin % (excluding other income) | -115 | Not captured | 20.5 | 9.3 |
Net profit (INR Cr) | -45.68 | 91.66 | 133.27 | 31.52 |
Net margin % | -407.9 | 7.5 | 13.2 | 7.7 |



